In vitro fertilization (IVF), infertility, miscarriage, chromosomal anomalies arising in female meiosis such as Trisomy 21 Down syndrome, mosaicism Other In vitro fertilization
Conditions
Interventions
Patients taking part in this study are undergoing a cycle of IVF treatment. If they participate in the study, they agree to provide half of the eggs that they produce to a research project, while the
Sponsors
University of Warwick
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: The inclusion criteria are the same as those applied clinically for patients sharing eggs with another person/couple. 1. Aged between 18 and 32 years 2. Normal ovarian reserve as determined by basal Follicle Stimulating Hormone (FSH) and estradiol (E2), antral follicle count, and anti-mullerian hormone (AMH) test 3. No hydrosalpinges 4. No large endometriotic ovarian cysts >3 cm 5. Body mass index between 19 and 30 kg/m² 6. Completed donor screening (transmissible diseases excluded, cytogenetic testing, and no family history of inherited disease) 7. No previous evidence of poor ovarian response 8. Informed consent provided 9. Independent counselling 10. No genetic disorder or history of recurrent miscarriage (=3) 11. Normal serum AMH 12. No evidence of adverse embryology in previous cycle (e.g. poor embryo or oocyte quality)
Exclusion criteria
Exclusion criteria: The exclusion criteria are the same as those applied clinically for patients sharing eggs with another person/couple. 1. Not in the required age range or BMI range 2. History of previous poor ovarian response or evidence of low ovarian reserve 3. Previous pregnancy loss due to fetal abnormality 4. Family history of inherited disease 5. Positive test results for viral risks (Human Immunodeficiency Virus [HIV], Hepatitis B, Hepatitis C, or Zika virus) or transmissible diseases 6. Medical contraindication to ovarian stimulation or oocyte recovery 7. Hydrosalpinges or large endometriotic ovarian cysts 8. Previous history of adverse embryology 9. Unwilling to have all screening tests 10. Unwilling to have independent counselling 11. Unwilling to consent to the research project
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Feasibility and supply of high-quality eggs from this source to support current and future research grant applications assessed from egg numbers received measured using clinical records at the time of egg collection for each patient, research projects undertaken measured using publication records and degree completions at the study end date, and grant applications received measured using financial records at the study end date | — |
Secondary
| Measure | Time frame |
|---|---|
| Pregnancy occurrence and outcome in participants following IVF treatment, assessed from clinical follow-up at the end of the patient’s treatment cycle (pregnancy test), live birth (at approximately 9 months after the end of the treatment cycle), and the study end date | — |
Countries
England, United Kingdom
Contacts
Public ContactGeraldine Hartshorne
Outcome results
None listed